Lorcinadol is an analgesic agent.

Ragaglitazar (DRF 2725, NNC 61-0029) is phenoxazine analog of phenyl propanoic acid having dual (PPARα and PPARγ) agonist property intended to restore insulin sensitivity and correct diabetic dyslipidemia. PPAR-α is highly expressed in liver and muscle and upon activation leads to decreases in plasma triglycerides and increases in HDL cholesterol levels. PPAR-γ activation leads to enhancement of glucose uptake in skeletal muscles and adipose tissue. Ragaglitazar provided the glycemic control that was comparable with that of pioglitazone and, compared with placebo, provided a significant improvement in the lipid profile.

Vofopitant (previously known as GR205171), a tetrazole-derivative, was developed as a neurokinin1 receptor antagonist. Vofopitant was studied in clinical trials phase II for the treatment of primary insomnia and posttraumatic stress disorder. However, these studies were discontinued due to lack of effectiveness. In addition, vofopitant participated in phase I for patients with bipolar disorder. However, this study was terminated because of the slow recruitment; trial unlikely to reach completion.

Glicondamide is a derivative of sulphonamides (antibacterial sulfa drugs). It acts by increasing the release of insulin from pancreatic beta cells, resulting in lower blood glucose levels.

Fenabutene controls pituitary activity.

Fencibutirol is alpha-cyclohexylbutyric acid derivative. It exerts choleretic activity.

IRAMPANEL, an oxazole derivative, is a dual non-competitive antagonist of the AMPA receptor and neuronal voltage-gated sodium channel blocker. It was under development for the potential treatment of stroke and other neurological disorders, including epilepsy and pain.

FIDUXOSIN is a selective alpha1-adrenoceptor antagonist with higher affinity for alpha1A-adrenoceptors and for alpha1D-adrenoceptors than for alpha1B-adrenoceptors. It was in clinical trials for the treatment of benign prostatic hyperplasia.

Varlitinib (Alternative Names: ARRY-334543; ARRY-543; ASLAN-001; Varlitinib tosylate) is a small molecule based reversible pan-HER inhibitor of EGFR, HER2 and HER4. In response to the binding of various ligands, these kinases undergo heterodimerisation and homodimerization, resulting in activation of numerous growth factor signaling pathways, by inhibiting the activation of the HER receptors via drug, effects such as shrinkage of the tumor and longer survival can be anticipated. In a large variety of cancers, the overexpression and/or constitutive activation of EGFR and HER2 are often observed and frequently correlate with poor clinical prognosis. Licensed from Array BioPharma with global rights for all indications, varlitinib is being developed as first-in-class drug for cholangiocarcinoma, gastric and colorectal cancer, and as best-in-class drug for breast cancer.

Dietifen is an anesthetic, vasodilator and antifungal agent. The main pharmacological feature of the drug is its ability to cause expansion of the coronary vessels. It also has a moderate spasmolytic activity (reduces spasms of the muscles of the intestine and other internal organs) and somewhat inhibits the conduction of nervous excitement through the vegetative nodes. Significant changes in blood pressure and pulse rate does not cause, does not possess hormonal (estrogenic) activity. It is indicated for the treatment of chronic coronary insufficiency, angina pectoris, severe forms of coronary sclerosis and pre-infarction conditions (simultaneously with anticoagulants).